SCHEMBL25422503

SCHEMBL25422503

Cn1cc(C(=O)Nc2ncc(Br)s2)ccc1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.55
SMN1; SMN2 Q16637 4/20 0.55
NPC1 O15118 4/20 0.55
LMNA P02545 3/20 0.55
PKM P14618 2/20 0.55
CREBBP Q92793 1/20 0.46
FBP1 P09467 4/20 0.45
MAPK10 P53779 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
CSNK2A3 Q8NEV1 1/20 0.44
CCNE1 P24864 2/20 0.43
CDK2 P24941 2/20 0.43
CDK5 Q00535 2/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 1/20 0.42
HDAC1 Q13547 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25271462 0.81 SMN1; SMN2 (0.46) RAB9ASMN1; SMN2NPC1LMNAPKM
SCHEMBL25609102 0.76 PDE10A (0.50) CREBBPCSNK2A2CSNK2A1KMT2A
SCHEMBL25612689 0.76 KDR (0.46) LMNACREBBPCSNK2A2CSNK2A1CCNE1
SCHEMBL836669 0.75 KDR (0.68) RAB9ASMN1; SMN2NPC1LMNAPKM
SCHEMBL31501375 0.75 CSNK2A2 (0.50) CREBBPCSNK2A2CSNK2A1KMT2A
SCHEMBL25610341 0.75 CSNK2A2 (0.50) CREBBPCSNK2A2CSNK2A1KMT2A
SCHEMBL17234188 0.73 SMN1; SMN2 (0.54) RAB9ASMN1; SMN2NPC1LMNAPKM
SCHEMBL25423524 0.73 WNT1 (0.48) SMN1; SMN2CREBBPCSNK2A2CSNK2A1CDK2
SCHEMBL21394526 0.73 SCD (0.60) RAB9ASMN1; SMN2NPC1LMNAMEN1
SCHEMBL29908276 0.73 STAT3 (0.64) RAB9ASMN1; SMN2NPC1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS PROTHENA BIOSCIENCES INC 2025-02-27 US disclosed
CN-118843626-A Heterocyclic compounds as DYRK1A inhibitors 普罗塞纳生物科学有限公司 2024-10-25 CN disclosed
EP-4444421-A2 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS Prothena Biosciences Limited (IE) 2024-10-16 EP disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed
WO-2023107714-A2 METHODS FOR TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066318-A1 HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS DYRK1A, DYRK2, DYRK1B RAB9A 731/4885SMN1; SMN2 551/4885NPC1 3120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.